Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005037812 - FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

Publication Number WO/2005/037812
Publication Date 28.04.2005
International Application No. PCT/GB2004/004392
International Filing Date 15.10.2004
IPC
C07D 307/68 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
307Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
02not condensed with other rings
34having two or three double bonds between ring members or between ring members and non-ring members
56with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
CPC
A61P 19/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
A61P 25/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
06Antimigraine agents
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
Applicants
  • ASTERAND UK LIMITED [GB]/[GB] (AllExceptUS)
  • CLARK, David, Edward [GB]/[GB] (UsOnly)
  • HARRIS, Neil, Victor [GB]/[GB] (UsOnly)
  • FENTON, Garry [GB]/[GB] (UsOnly)
  • HYND, George [GB]/[GB] (UsOnly)
  • STUTTLE, Keith, Alfred, James [GB]/[GB] (UsOnly)
  • SUTTON, Jonathan, Mark [GB]/[GB] (UsOnly)
  • OXFORD, Alexander, William [GB]/[GB] (UsOnly)
  • DAVIS, Richard, Jon [GB]/[GB] (UsOnly)
  • COLEMAN, Robert, Alexander [GB]/[GB] (UsOnly)
  • CLARK, Kenneth, Lyle [GB]/[GB] (UsOnly)
Inventors
  • CLARK, David, Edward
  • HARRIS, Neil, Victor
  • FENTON, Garry
  • HYND, George
  • STUTTLE, Keith, Alfred, James
  • SUTTON, Jonathan, Mark
  • OXFORD, Alexander, William
  • DAVIS, Richard, Jon
  • COLEMAN, Robert, Alexander
  • CLARK, Kenneth, Lyle
Agents
  • WATSON, Robert
Priority Data
0324269.016.10.2003GB
60/512,20020.10.2003US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
(FR) DERIVES DE FURANE UTILISES COMME ANTAGONISTES DU RECEPTEUR EP4
Abstract
(EN) A compound of formula: (I); or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii)an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m + n = 1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula: (II); (iii) a group of formula: (III); wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4 , where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.
(FR) L'invention concerne un composé représenté par la formule: (I); ou un sel, un solvate et une forme chimiquement protégée de celui-ci, R2 ou R5 représentant: (i) H ou un groupe alkyle C1-4 éventuellement substitué, ou (ii) un aryle C5-7 éventuellement substitué; le R2 ou R5 restant représente l'autre groupe; m et n peuvent représenter 0 ou 1, et m + n = 1 ou 2, RN représente H ou alkyle C1-4 éventuellement substitué, R3 représente soit: (i) carboxy; soit (ii) un groupe représenté par la formule (II): (II); (iii) un groupe représenté par la formule (III): (III); dans lesquelles R représente alkyle C1-7 éventuellement substitué, aryle C5-20, ou NRN3RN4, dans cette dernière formule RN3 et RN4 sont choisis séparément dans alykle C1-4 éventuellement substitué, ou (iv) tétrazol-5-yl.
Related patent documents
US2007135503This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
NO20062187This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau